Document is current
Any future updates will be listed below
-
Authors
Medford, Arielle J.
Dubash, Taronish D.
Juric, Dejan
Spring, Laura
Niemierko, Andrzej
Vidula, Neelima
Peppercorn, Jeffrey
Isakoff, Steven
Reeves, Brittany A.
LiCausi, Joseph A.
Wesley, Benjamin
Malvarosa, Giuliana
Yuen, Megan
Wittner, Ben S. https://orcid.org/0000-0001-5657-9849
Lawrence, Michael S.
Iafrate, A. John
Ellisen, Leif
Moy, Beverly
Toner, Mehmet
Maheswaran, Shyamala
Haber, Daniel A.
Bardia, Aditya
- License Information
-
More Information
Article History
Received: 21 January 2019
Accepted: 13 June 2019
First Online: 16 July 2019
Competing interests
: MGH has filed for patent protection for the CTC-iChip technology. D.J. has served as a Consultant/Advisory Board at Novartis, Genentech, Eisai, Ipsen, and EMD Serono. L.S. has served as a Consultant/Advisory Board at Novartis. S.I. has served as a Consultant/Advisory Board at Abbvie, PharaMar, Genentech/Roche, Myriad Genetics, Hengrui Therapeutics, Puma Biotech, and Immunomedics. B.M. spouse has served as a Consultant/Advisory Board at MOTUS GI. A.J.I has served as a Consultant/Advisory Board at Roche, Chugai, Constellation, and Pfizer, and has ownership interests and intellectual property rights/inventor/patent holder at ArcherDx. A.B. has served as a Consultant/Advisory Board at Novartis, Pfizer, Genentech/Roche, Radius Health, Merck, Spectrum pharma, Immunomedics, Sanofi, Daiichi Pharma, and Taiho Oncology, and has research Grant from Biothernostics (self), Genentech (institution), Novartis (institution), Pfizer (institution), Merck (institution), Sanofi (institution), Radius Health (institution), Immunomedics (institution), Mersana(institution), and Innocrin (institution). All other authors declare no competing interests.
